Richard Thomas Layer
Hearing Aid Provider in Salt Lake City, UT
License number
Utah 5177563-8914
Issued Date
Nov 15, 2002
Expiration Date
May 31, 2007
Category
xControlled Substance Handler
Type
Controlled Substance Handler Individual
Address
Address
Salt Lake City, UT
Personal information
See more information about Richard Thomas Layer at radaris.comName
Address
Phone
9024 Sunburst Ct, Sandy, UT 84093
Professional information
Use Of Conantokins
US Patent:
6399574, Jun 4, 2002
Filed:
Mar 22, 2000
Appl. No.:
09/533889
Inventors:
R. Tyler McCabe - Salt Lake City UT
Li-Ming Zhou - Salt Lake City UT
Richard T. Layer - Salt Lake City UT
Baldomero M. Olivera - Salt Lake City UT
J. Michael McIntosh - Salt Lake City UT
Li-Ming Zhou - Salt Lake City UT
Richard T. Layer - Salt Lake City UT
Baldomero M. Olivera - Salt Lake City UT
J. Michael McIntosh - Salt Lake City UT
Assignee:
University of Utah Research Foundation - Salt lake City UT
Cognetix, Inc. - Salt lake City UT
Cognetix, Inc. - Salt lake City UT
International Classification:
A61K 3800
US Classification:
514 12, 514 2, 514 13, 530300, 530326, 530324, 530325, 4241851
Abstract:
The present invention is directed to the use of conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more -carboxyglutamic acid residues, for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents. Neurologic disorders and psychiatric disorders include, epilepsy, convulsions, neurotoxic injury (associated with conditions of hypoxia, anoxia or ischemia which typically follows stroke, cerebrovascular accident, brain or spinal cord trauma, myocardial infarct, physical trauma, drowning, suffocation, perinatal asphyxia, or hypoglycemic events), neurodegeneration (associated with Alzheimers disease, senile dementia, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinsons disease, Huntingtons disease, Downs Syndrome, Korsakoffs disease, schizophrenia, AIDS dementia, multi-infarct dementia, Binswanger dementia and neuronal damage associated with uncontrolled seizures), chemical toxicity (such as addiction, morphine tolerance, opiate tolerance, opioid tolerance and barbiturate tolerance), pain (acute, chronic, migraine), anxiety, major depression, manic-depressive illness, obsessive-complusive disorder, schizophrenia and mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and dystonia (movement disorder), sleep disorder, muscle relaxation and urinary incontinence. In addition, the conantokins are useful for treating HIV infection, ophthalmic indications and memory, learning or cognitive deficits.
Conantokins
US Patent:
6515103, Feb 4, 2003
Filed:
May 11, 2000
Appl. No.:
09/142080
Inventors:
Fe C. Abogadie - London, GB
Lourdes J. Cruz - Salt Lake City UT
Baldomero M. Olivera - Salt Lake City UT
Craig Walker - Salt Lake City UT
Clark Colledge - Alpine UT
David R. Hillyard - Salt Lake City UT
Elsie Jimenez - Qyezan, PH
Richard T. Layer - Salt Lake City UT
Li-Ming Zhou - Salt Lake City UT
Gregory S. Shen - Salt Lake City UT
R. Tyler McCabe - Salt Lake City UT
Jean E. Rivier - La Jolla CA
Lourdes J. Cruz - Salt Lake City UT
Baldomero M. Olivera - Salt Lake City UT
Craig Walker - Salt Lake City UT
Clark Colledge - Alpine UT
David R. Hillyard - Salt Lake City UT
Elsie Jimenez - Qyezan, PH
Richard T. Layer - Salt Lake City UT
Li-Ming Zhou - Salt Lake City UT
Gregory S. Shen - Salt Lake City UT
R. Tyler McCabe - Salt Lake City UT
Jean E. Rivier - La Jolla CA
Assignee:
University of Utah Research Foundation - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT
Salk Institute - LaJolla CA
Cognetix, Inc. - Salt Lake City UT
Salk Institute - LaJolla CA
International Classification:
A61K 3800
US Classification:
530326, 530300, 530327, 514 13, 514 14, 514 15, 514 21
Abstract:
The present invention is directed to conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more -carboxyglutamic acid residues. The conantokins are useful for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents.
Use Of Conantokins
US Patent:
6172041, Jan 9, 2001
Filed:
Feb 10, 1999
Appl. No.:
9/142078
Inventors:
R. Tyler McCabe - Salt Lake City UT
Li-Ming Zhou - Salt Lake City UT
Richard T. Layer - Salt Lake City UT
Baldomero M. Olivera - Salt Lake City UT
J. Michael McIntosh - Salt Lake City UT
Li-Ming Zhou - Salt Lake City UT
Richard T. Layer - Salt Lake City UT
Baldomero M. Olivera - Salt Lake City UT
J. Michael McIntosh - Salt Lake City UT
Assignee:
University of Utah Research Foundation - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT
International Classification:
A61K 3800, C07K 500, C07K 700
US Classification:
514 12
Abstract:
The present invention is directed to the use of conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more. gamma. -carboxyglutamic acid residues, for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents. Neurologic disorders and psychiatric disorders include epilepsy, convulsions, neurotoxic injury (associated with conditions of hypoxia, anoxia or ischemia which typically follows stroke, cerebrovascular accident, brain or spinal cord trauma, myocardial infarct, physical trauma, drowning, suffocation, perinatal asphyxia, or hypoglycemic events), neurodegeneration (associated with Alzheimer's disease, senile dementia, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson's disease, Huntington's disease, Down's Syndrome, Korsakoff's disease, schizophrenia, AIDS dementia, multi-infarct dementia, Binswanger dementia and neuronal damage associated with uncontrolled seizures), chemical toxicity (such as addiction, morphine tolerance, opiate tolerance, opioid tolerance and barbiturate tolerance), pain (acute, chronic, migraine), anxiety, major depression, manic-depressive illness, obsessive-compulsive disorder, schizophrenia and mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and dystonia (movement disorder), sleep disorder, muscle relaxation and urinary incontinence. In addition, the conantokins are useful for treating HIV infection, ophthalmic indications and memory, learning or cognitive deficits.